Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective

BACKGROUND: A herpes zoster vaccine has been approved by the FDA for use in prevention of herpes zoster in individuals who are aged 50 years or older. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination only in individuals who are aged 60 years and older. OBJECTIVES: To (a...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Jonathan, Mauskopf, Josephine, Kawai, Kosuke, Johnson, Kelly D., Xu, Ruifeng, Acosta, Camilo J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397635/
https://www.ncbi.nlm.nih.gov/pubmed/27348287
http://dx.doi.org/10.18553/jmcp.2016.22.7.872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397635/
https://www.ncbi.nlm.nih.gov/pubmed/27348287
http://dx.doi.org/10.18553/jmcp.2016.22.7.872

Ejemplares similares